These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15531300)

  • 1. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
    Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
    Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
    Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
    J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
    Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
    Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
    Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
    J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-arthritis effect of a novel quinazoline derivative through inhibiting production of TNF-α mediated by TNF-α converting enzyme in murine collagen-induced arthritis model.
    Pu Y; Cao D; Xie C; Pei H; Li D; Tang M; Chen L
    Biochem Biophys Res Commun; 2015 Jul; 462(4):288-93. PubMed ID: 25935488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
    Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
    J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis.
    Ohta S; Harigai M; Tanaka M; Kawaguchi Y; Sugiura T; Takagi K; Fukasawa C; Hara M; Kamatani N
    J Rheumatol; 2001 Aug; 28(8):1756-63. PubMed ID: 11508576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
    J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
    Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
    Tsuji F; Oki K; Okahara A; Suhara H; Yamanouchi T; Sasano M; Mita S; Horiuchi M
    Cytokine; 2002 Mar; 17(6):294-300. PubMed ID: 12061836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
    Sumariwalla PF; Palmer CD; Pickford LB; Feldmann M; Foxwell BM; Brennan FM
    Rheumatology (Oxford); 2009 Jan; 48(1):32-8. PubMed ID: 19015145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of TACE inhibition.
    Newton RC; Solomon KA; Covington MB; Decicco CP; Haley PJ; Friedman SM; Vaddi K
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii25-32. PubMed ID: 11890648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
    Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
    J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of tumor necrosis factor-α converting enzyme (TACE) enhances IL-1β and IFN-γ via caspase-1 activation: a probable cause for loss of efficacy of TACE inhibitors in humans?
    Sharma M; Mohapatra J; Acharya A; Deshpande SS; Chatterjee A; Jain MR
    Eur J Pharmacol; 2013 Feb; 701(1-3):106-13. PubMed ID: 23266381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse hydroxamate-based selective TACE inhibitors.
    Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
    Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.